Zomedica (ZOM) Stock Price, News & Analysis

Company Overview

Zomedica Pharmaceuticals Corp. is a veterinary health company dedicated to improving the lives of companion animals through innovative diagnostic and therapeutic solutions. The company’s primary focus is on the development of point‐of‐care veterinary diagnostics and disease‐specific pharmaceuticals, aimed at empowering practitioners with timely information and treatment options for cats and dogs. Zomedica’s flagship offering is TRUFORMA, a bench‐top diagnostic platform designed to deliver rapid, accurate in‐clinic test results across a range of analytes including thyroid hormones, cortisol and infectious disease biomarkers.

Beyond diagnostics, Zomedica is advancing its therapeutic pipeline with products targeting unmet needs in feline and canine health. Notably, the company is developing Palinveo, an oral treatment for hyperthyroidism in cats, currently progressing through regulatory review. By integrating diagnostics and targeted pharmaceuticals, Zomedica seeks to create a comprehensive “test‐and‐treat” ecosystem that enables veterinarians to diagnose and manage endocrine and metabolic disorders within a single practice setting.

Founded in the early 2010s and headquartered in Ann Arbor, Michigan, Zomedica serves veterinary clinics across the United States and Canada, with plans to expand into additional international markets. Under the leadership of President and Chief Executive Officer Robert Cohen, the company has built strategic partnerships with veterinary distributors and academic research institutions to accelerate product development and market adoption. With a growing commercial footprint and a pipeline of novel products, Zomedica aims to become a leading provider of veterinary diagnostics and therapies for companion animal health.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 790,936 shs
• Average Volume: 4.72 million shs
• Market Capitalization: $95.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ZOM Stock Analysis - Frequently Asked Questions

How were Zomedica's earnings last quarter?

Zomedica Corp. (NYSEAMERICAN:ZOM) issued its earnings results on Thursday, November, 7th. The company reported ($0.01) earnings per share (EPS) for the quarter. The firm earned $7 million during the quarter. Zomedica had a negative trailing twelve-month return on equity of 12.47% and a negative net margin of 232.88%.
Read the conference call transcript.

How do I buy shares of Zomedica?

Shares of ZOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Zomedica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Zomedica investors own include Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT), Phunware (PHUN) and

Company Calendar

• Last Earnings: 11/07/2024
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:ZOM
• CIK: 1684144
• Web: www.zomedica.com
• Phone: 734-369-2555
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.53 million
• Net Margins: -232.88%
• Pretax Margin: -232.24%
• Return on Equity: -12.47%
• Return on Assets: -11.84%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.82
• Quick Ratio: 10.15

Sales & Book Value

• Annual Sales: $25.19 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.24 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 979,950,000
• Free Float: 938,890,000
• Market Cap: $95.35 million
• Optionable: Not Optionable
• Beta: 1.03